Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Among patients with previously untreated chronic lymphocytic leukemia, ibrutinib–venetoclax therapy with treatment duration guided by measurable residual disease status resulted in better outcomes than standard chemotherapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-01, Vol.390 (4), p.326-337
Hauptverfasser:	Munir, Talha, Cairns, David A., Bloor, Adrian, Allsup, David, Cwynarski, Kate, Pettitt, Andrew, Paneesha, Shankara, Fox, Christopher P., Eyre, Toby A., Forconi, Francesco, Elmusharaf, Nagah, Kennedy, Ben, Gribben, John, Pemberton, Nicholas, Sheehy, Oonagh, Preston, Gavin, Schuh, Anna, Walewska, Renata, Duley, Lelia, Howard, Dena, Hockaday, Anna, Jackson, Sharon, Greatorex, Natasha, Girvan, Sean, Bell, Sue, Brown, Julia M., Webster, Nichola, Dalal, Surita, de Tute, Ruth, Rawstron, Andrew, Patten, Piers E.M., Hillmen, Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Bioavailability Bone marrow Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Chromosomes Chronic lymphocytic leukemia Confidence intervals Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Duration of Therapy Ethics Fludarabine Hematology Humans Hypothesis testing Inhibitor drugs Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - pathology Lymphoma Neoplasm, Residual - pathology Oncology Peripheral blood Rituximab Rituximab - administration & dosage Rituximab - adverse effects Sulfonamides - administration & dosage Sulfonamides - adverse effects Survival Targeted cancer therapy Time Factors Toxicity Treatments in Oncology Vidarabine - administration & dosage Vidarabine - adverse effects Vidarabine - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among patients with previously untreated chronic lymphocytic leukemia, ibrutinib–venetoclax therapy with treatment duration guided by measurable residual disease status resulted in better outcomes than standard chemotherapy.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2310063